Interleukin-33 as a potential indicator of disease activity in rheumatoid arthritis: a case-control study.
文献摘要
Background Rheumatoid arthritis (RA) is a chronic autoimmune disease marked by persistent inflammation and progressive joint damage. Interleukin-33 (IL-33) has been proposed as an indicator of disease activity; however, its clinical relevance remains controversial, as studies report both pro- and anti-inflammatory effects. Methods This case-control study included 44 patients with RA and 44 age- and sex-matched healthy controls recruited from Minia University Hospital, Egypt. Serum IL-33 levels, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF) and Disease Activity Score - 28-ESR (DAS28- ESR) were obtained. Medications, specifically disease-modifying antirheumatic drugs (DMARDs), were recorded. Associations between IL-33 levels and clinical and laboratory parameters were evaluated. Multivariate regression analysis and receiver operating characteristic (ROC) analysis were performed. Results Serum IL-33 levels were significantly elevated in patients with rheumatoid arthritis, with a median of 145 (interquartile range 41.75-193.75), compared to 7 (4.25-11.0) in controls (p 2 = 0.83). ROC curve analysis also showed good discrimination for high disease activity (n = 8)(AUC = 0.918, 95% CI: 0.807-0.986). At the selected IL-33 cut-off of 300 pg/mL, sensitivity was 66.7% and specificity was 100%. Conclusions Serum IL-33 levels are strongly associated with disease activity in RA and may be an indicator of inflammatory burden.